Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13358MR)

This product GTTS-WQ13358MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13358MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15403MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ6073MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10886MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ3257MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ5558MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ15509MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ15589MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW